Shanxi Kangbao Biological Product Co. Ltd.

Objective To establish a method for the determination of antimony content in human prothrombin complex.Methods The content of antimony in human prothrombin complex was determined by hydride generation-at. absorption spectrometry.Results The calibration curve of antimony was linear in the range of 0-25.0 ng/mL with correlation coefficient higher than 0.99.The detection limit was 0.553 3 ng/mL and the quant. limit was 1.844 ng/mL.The recoveries were 95.93%-118.62%.Conclusion The method is simple,rapid,accurate and sensitive,and can be suitable for the determination of antimony in human prothrombin complex.

To determine content of residual organic solvents of ethanol, dichloromethane, chloroform, tetra-hydrofuran, N,N-dimethylformamide in mirtazapine, the capillary gas chromatog. method was established.HP-1 capillary column (30 m×0.53 mm, 3 μm) was selected, the solvent was DMSO, the carrier gas was nitrogen, and FID detector was used.The five kinds of organic solvents had good linear relationship at ranges of 100.008-1 000.080 μg·mL^-1, 12.124-121.244 μg·mL^-1, 1.202-12.016 μg·mL^-1, 14.433-144.328 μg·mL^-1, 17.659-176.592 μg·mL^-1resp.The min. detectable quantity were 1.03 μg·mL^-1, 0.83 μg·mL^-1, 0.47 μg·mL^-1, 0.32 μg·mL^-1, 1.04 μg·mL^-1, resp.The average recoveries were 99.21%, 98.72%, 99.38%, 99.03%, 99.29% resp.The precision RSD was all less than 1%.This method is sensitive and accurate, which can be used to determine the residual organic solvents in mirtazapine.

The anti-cancer effects and the tumor-targeting of rhVEGF_121KDR/rGEL fusion toxin in human tumor xenografts models were investigated for the development of more effective and safer anticancer drugs.Human carcinoma xenografts models of hepatoma SMMC-7721 cells, esophageal carcinoma KYSE-150 cells, gastric carcinoma SGC-7901 cells and colon carcinoma HT-29 cells were established, tumor volume was measured every 2-3 days after administration, tumor growth curve was drawn, and the relative tumor growth rate was calculatedThe localization of fusion toxin in tumor tissues was examined by immunohistochem.The volume of human carcinoma xenografts of SMMC-7721, KYSE-150, SGC-7901 and HT-29 was resp. (89.33 ± 56.36) mm³, (142.47 ± 58.67) mm³, (73.80 ± 31.05) mm³ and (79.64 ± 34.46) mm³ in the treated group, and (328.19 ± 200.27) mm³, (474.05 ± 167.42) mm³, (172.34 ± 41.78) mm³ and (480.26 ± 348.34) mm³ in the untreated group.The relative tumor volume (RTV) of the four human carcinoma xenografts in the treated group was resp. 5.31 ± 2.13, 5.72 ± 2.45, 3.59 ± 1.55 and 5.82 ± 1.92, and in untreated group, the RTV was resp. 17.10 ± 6.00, 23.71 ± 10.36, 11.65 ± 4.14 and 23.24 ± 5.74.The relative growth rate was resp. 31.05%, 24.12%, 25.04% and 30.82%.Both tumor volume and RTV of human carcinoma xenografts treated with the fusion toxin demonstrated significant reduction compared with untreated controls (all P < 0.01).In conclusion, the rhVEGF_121KDR/rGEL could significantly inhibit tumor growth in at least four xenograft models, and was a promising candidate drug for the targeted therapy of cancer.